Beclomethasone dipropionateCorticosteroid used for asthma and rhinitis CAS# 5534-09-8 |
- Leupeptin, Microbial
Catalog No.:BCC1217
CAS No.:103476-89-7
- AEBSF.HCl
Catalog No.:BCC1219
CAS No.:30827-99-7
- PMSF
Catalog No.:BCC1229
CAS No.:329-98-6
- Nafamostat Mesylate(FUT-175)
Catalog No.:BCC1228
CAS No.:82956-11-4
- Aprotinin
Catalog No.:BCC1220
CAS No.:9087-70-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 5534-09-8 | SDF | Download SDF |
| PubChem ID | 21700 | Appearance | Powder |
| Formula | C28H37ClO7 | M.Wt | 521.04 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (191.92 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate | ||
| SMILES | CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)Cl)O)C)C)OC(=O)CC | ||
| Standard InChIKey | KUVIULQEHSCUHY-XYWKZLDCSA-N | ||
| Standard InChI | InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Beclometasone dipropionate is a potent glucocorticoid agonist; it is a prodrug of the free form, beclometasone.
IC50 Value: 0.2 nM (Inhibiting thymidine incorporation) [1]
Target: glucocorticoid receptor
in vitro: Cortisol and beclomethasone dipropionate were more potent than salbutamol in inhibiting thymidine incorporation with IC50 values of 5 nM and 0.2 nM respectively. Cortisol 100 nM led to a 16.6 +/- 6.5% reduction and beclomethasone dipropionate 3 nM led to a 17.8 +/- 5.8% reduction in cell number [1].
in vivo: Controlled trials involving 497 adults and children demonstrated similar clinical efficacy between nebulized BDP and either nebulized fluticasone propionate or nebulized budesonide. Meta-analyses show that BDP, like other inhaled corticosteroids, has no major influence on patient height, urinary cortisol concentration, or bone metabolism [2]. Beclometasone dipropionate (BDP) 800 microgday(-1) suspension for nebulization and budesonide (BUD) 750 microg day(-1) given by nebulization in a twice-daily regimen, and when used in addition to the usual maintenance therapy, resulted in comparable clinical efficacy across all parameters [3].
Clinical trial: Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma. Phase 3 References: | |||||
Beclomethasone dipropionate Dilution Calculator
Beclomethasone dipropionate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9192 mL | 9.5962 mL | 19.1924 mL | 38.3848 mL | 47.981 mL |
| 5 mM | 0.3838 mL | 1.9192 mL | 3.8385 mL | 7.677 mL | 9.5962 mL |
| 10 mM | 0.1919 mL | 0.9596 mL | 1.9192 mL | 3.8385 mL | 4.7981 mL |
| 50 mM | 0.0384 mL | 0.1919 mL | 0.3838 mL | 0.7677 mL | 0.9596 mL |
| 100 mM | 0.0192 mL | 0.096 mL | 0.1919 mL | 0.3838 mL | 0.4798 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Beclomethasone dipropionate(BDP) is a topically active and anti-inflammatory corticosteroid used in treatment of asthma and rhinitis [1].
Beclomethasone dipropionate(BDP) is a topically active and anti-inflammatory corticosteroid used in treatment of asthma and rhinitis. In addition, Beclomethasone dipropionate has been reported to be previously developed as aqueous nasal formulations for the treatment of Allergic rhinitis. Moreover, Beclomethasone dipropionate has shown the availability in dry nasal aerosol formulations as chiorofluoro carbon metered-dose inhaler nasal sprays [1].
References:
[1] Ratner PH1, Melchior A, Dunbar SA, Tantry SK, Dorinsky PM. Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study. Clin Ther. 2012 Jun;34(6):1422-31.
- Petasiphenone
Catalog No.:BCC8100
CAS No.:162616-81-1
- Soyasaponin II
Catalog No.:BCN1418
CAS No.:55319-36-3
- Atherosperminine
Catalog No.:BCN8208
CAS No.:5531-98-6
- Costunolide
Catalog No.:BCN5740
CAS No.:553-21-9
- Xanthyletin
Catalog No.:BCN6722
CAS No.:553-19-5
- Thonzonium Bromide
Catalog No.:BCC5636
CAS No.:553-08-2
- Tiamulin
Catalog No.:BCC9179
CAS No.:55297-95-5
- (Z)-Falcarindiol
Catalog No.:BCN8495
CAS No.:55297-87-5
- Atractylodin
Catalog No.:BCN6292
CAS No.:55290-63-6
- Praziquantel
Catalog No.:BCC4829
CAS No.:55268-74-1
- MnTBAP Chloride
Catalog No.:BCC6477
CAS No.:55266-18-7
- Boc-Gln(Xan)-OH
Catalog No.:BCC3385
CAS No.:55260-24-7
- Vidarabine
Catalog No.:BCC4877
CAS No.:5536-17-4
- Baohuoside II
Catalog No.:BCN2888
CAS No.:55395-07-8
- Hydroxyisoleucine
Catalog No.:BCN8402
CAS No.:55399-93-4
- Lithium carbonate
Catalog No.:BCC7970
CAS No.:554-13-2
- Methazolamide
Catalog No.:BCC2318
CAS No.:554-57-4
- Deferasirox Fe3+ chelate
Catalog No.:BCC1521
CAS No.:554435-83-5
- 8beta-(4-Hydroxytigloyloxy)ovatifolin
Catalog No.:BCN7122
CAS No.:554449-27-3
- Boc- D-1-Nal-OH
Catalog No.:BCC3283
CAS No.:55447-00-2
- Anisodamine hydrobromide
Catalog No.:BCC8119
CAS No.:55449-49-5
- Z-Asp(OtBu)-OH.H2O
Catalog No.:BCC2789
CAS No.:5545-52-8
- Chimonanthine
Catalog No.:BCN7824
CAS No.:5545-89-1
- Jujuboside A
Catalog No.:BCN4949
CAS No.:55466-04-1
Humidity affects the morphology of particles emitted from beclomethasone dipropionate pressurized metered dose inhalers.[Pubmed:28167262]
Int J Pharm. 2017 Mar 30;520(1-2):207-215.
The effects of propellant type, cosolvent content, and air humidity on the morphology and solid phase of the particles produced from solution pressurized metered dose inhalers containing the corticosteroid Beclomethasone dipropionate were investigated. The active ingredient was dissolved in the HFA propellants 134a and 227ea with varying levels of the cosolvent ethanol and filled into pressurized metered dose inhalers. Inhalers were actuated into an evaporation chamber under controlled temperature and humidity conditions and sampled using a single nozzle, single stage inertial impactor. Particle morphology was assessed qualitatively using field emission scanning electron microscopy and focused ion beam-helium ion microscopy. Drug solid phase was assessed using Raman microscopy. The relative humidity of the air during inhaler actuation was found to have a strong effect on the particle morphology, with solid spheroidal particles produced in dry air and highly porous particles produced at higher humidity levels. Air humidification was found to have no effect on the solid phase of the drug particles, which was predominantly amorphous for all tested formulations. A critical level of air relative humidity was required to generate porous particles for each tested formulation. This critical relative humidity was found to depend on the amount of ethanol used in the inhaler, but not on the type of propellant utilized. The results indicate that under the right circumstances water vapor saturation followed by nucleated water condensation or ice deposition occurs during particle formation from evaporating propellant-cosolvent-BDP droplets. This finding reveals the importance of condensed water or ice as a templating agent for porosity when particle formation occurs at saturated conditions, with possible implications on the pharmacokinetics of solution pMDIs and potential applications in particle engineering for drug delivery.
Polymeric drug delivery micelle-like nanocarriers for pulmonary administration of beclomethasone dipropionate.[Pubmed:28013164]
Colloids Surf B Biointerfaces. 2017 Mar 1;151:206-214.
In this paper, the potential of novel polymeric micelles as drug delivery systems for Beclomethasone dipropionate (BDP) administration into the lung is investigated. These nanostructures are obtained starting from alpha,beta-poly(N-2-hydroxyethyl)-d,l-aspartamide (PHEA), which was subsequently functionalized with O-(2-aminoethyl)-O'-methylpolyethylenglycole (PEG2000), ethylenediamine (EDA) and lipoic acid (LA), obtaining PHEA-PEG2000-EDA-LA graft copolymer. Empty and drug-loaded micelles possess adequate chemical-physical characteristics for pulmonary administration such as spherical shape, slightly positive surface charge and mean size of about 200nm. Besides, BDP-loaded micelles, obtained with a Drug Loading equal to 5wt%, result to be stable in physiological-mimicking media, protecting the drug from hydrolysis and giving a sustained drug release profile. Moreover, the micelle-like structure and surface characteristics seems to improve drug permeation through the mucus layer. Finally, it is also demonstrated that BDP-loaded PHEA-PEG2000-EDA-LA micelles are able to increase cell uptake of BDP of about 44wt% compared to Clenil((R)) on 16-HBE cells and possess an higher biocompatibility in comparison with the same commercial formulation.
Comparison of clinical effects of beclomethasone dipropionate & budesonide in treatment of children with mild persistent asthma: A double-blind, randomized, controlled study.[Pubmed:27934805]
Indian J Med Res. 2016 Aug;144(2):250-257.
BACKGROUND & OBJECTIVES: Various inhaled corticosteroids (ICSs) are available to control the symptoms of asthma. Although Beclomethasone dipropionate (BDP) and budesonide (BUD) are one of the oldest ICSs, their wide availability and low cost make them attractive options in developing countries. Due to lack of consensus on which of the two drugs is better for controlling mild persistent asthma, we undertook this study to compare the efficacy of these two drugs by measuring the change in percentage predicted forced expiratory volume in one second (FEV 1 ) from baseline in children with mild persistent asthma. METHODS: A double-blind, randomized, parallel group study was conducted in children 7-15 yr of age with newly diagnosed asthma. Of the 85 cases of mild persistent asthma, 42 received BUD while 43 received BDP at a dose of 400 microg/day using pressurized metered-dose inhaler with valved spacer for two months. The outcomes measured were change in FEV 1 , symptom scores and side effects. RESULTS: There was a significant (P < 0.05) improvement in FEV 1 in BUD group (98.43 +/- 4.63%) than in BDP group (95.65 +/- 5.66%) at the end of two months of treatment. The mean symptom scores in BUD group (0.28 +/- 1.22) and BDP group (0.43 +/- 1.52) were comparable after two months. No side effects were seen in either group. INTERPRETATION & CONCLUSIONS: FEV 1 was significantly greater in BUD group than BDP group. Improvement in symptoms and incidence of side effects were similar. Our findings indicate that both BDP and BUD can be used effectively in the management of children with mild persistent asthma. [CTRI No: CTRI/2013/03/003495].
Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis.[Pubmed:27873507]
Yonsei Med J. 2017 Jan;58(1):144-149.
PURPOSE: Our aim was to evaluate the efficacy and safety of oral Beclomethasone dipropionate (BDP) in Korean patients with ulcerative colitis (UC). MATERIALS AND METHODS: The medical records of patients with active UC who were treated with BDP were retrospectively reviewed. Partial Mayo Clinic score (pMS) was calculated to determine disease activity. After 4 weeks of therapy, clinical remission, clinical response, and response failure rates were evaluated. Clinical remission was defined as a post-treatment pMS of 0 or 1, clinical response as a decrease of two of three points in pMS and >30% from baseline, and response failure as a lack of clinical response. Also, we considered that clinical remission was included in clinical response. RESULTS: Between July 2013 and April 2015, 95 patients with UC received BDP therapy at our institution (median age, 44 years; range, 12-81 years). After 4 weeks of therapy, clinical remission and clinical response rates were 50.5% and 73.7%, respectively. Mean change of pMS before and after BDP therapy was 2.4. There was no significant side effect reported. In multivariate analysis, disease activity was the only factor associated with a favorable response. Clinical remission rate was significantly higher in the mild disease activity group (66.7%) than that in the moderate or severe disease activity group (41.9%) (p=0.024). CONCLUSION: BDP is efficacious in inducing a clinical response or remission in Korean patients with UC. Patients with mild UC were more likely to be in remission than those with moderate or severe UC after receiving BDP for 4 weeks. BDP exhibited a good safety profile.
